1. A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. (August 2020) Authors: Reck, Martin; Luft, Alexander; Bondarenko, Igor; Shevnia, Serhii; Trukhin, Dmytro; Kovalenko, Nadezhda V.; Vacharadze, Kakha; Andrea, Fülöp; Hontsa, Anatoliy; Choi, Jihye; Shin, Donghoon Journal: Lung cancer Issue: Volume 146(2020) Page Start: 12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. Issue 3 (December 2015) Authors: Schmid-Bindert, Gerald; Engel-Riedel, Walburga; Reck, Martin; Schuette, Wolfgang; Stöhlmacher, Jan; Fischer, Jürgen R.; Mazières, Julien; Chouaid, Christos; Wolf, Martin; Vinolas, Nuria; Soldatenkova, Victoria; Ripoche, Veronique; Nguyen, Tuan; Visseren-Grul, Carla Journal: Lung cancer Issue: Volume 90:Issue 3(2015:Dec.) Page Start: 397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). (September 2016) Authors: Smit, Egbert F.; Wu, Yi-Long; Gervais, Radj; Zhou, Caicun; Felip, Enriqueta; Feng, Jifeng; Guclu, Salih Zeki; Hoiczyk, Mathias; Dorokhova, Elena; Freudensprung, Ulrich; Grange, Susan; Perez-Moreno, Pablo Diego; Mitchell, Lada; Reck, Martin Journal: Lung cancer Issue: Volume 99(2016) Page Start: 94 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. Issue 7 (20th July 2022) Authors: Peters, Solange; Paz-Ares, Luis; Herbst, Roy S; Reck, Martin Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 7(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. (May 2021) Authors: Brückl, Wolfgang M.; Reck, Martin; Griesinger, Frank; Schäfer, Harald; Kortsik, Cornelius; Gaska, Tobias; Rawluk, Justyna; Krüger, Stefan; Kokowski, Konrad; Budweiser, Stephan; Ficker, Joachim H.; Hoffmann, Christopher; Schüler, Andrea; Laack, Eckart Journal: Therapeutic advances in medical oncology Issue: Volume 13(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227). Issue 2 (December 2015) Authors: Hellmann, Matthew; Ramalingam, Suresh; Reck, Martin; O'Byrne, Ken; Paz-Ares, Luis; Harbison, Christopher; Bhagavatheeswaran, Prabhu; Nathan, Faith; Brahmer, Julie Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227). (4th November 2015) Authors: Hellmann, Matthew; Ramalingam, Suresh; Reck, Martin; O'Byrne, Ken; Paz-Ares, Luis; Harbison, Christopher T; Bhagavatheeswaran, Prabhu; Nathan, Faith; Brahmer, Julie Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Issue 3 (February 2015) Authors: Novello, Silvia; Kaiser, Rolf; Mellemgaard, Anders; Douillard, Jean-Yves; Orlov, Sergey; Krzakowski, Maciej; von Pawel, Joachim; Gottfried, Maya; Bondarenko, Igor; Liao, Meilin; Barrueco, José; Gaschler-Markefski, Birgit; Griebsch, Ingolf; Palmer, Michael; Reck, Martin; LUME-Lung 1 Study Group Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: 317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Anesthetic Influence on Occurrence and Treatment of the Trigemino-Cardiac Reflex. Issue 18 (May 2015) Authors: Meuwly, Cyrill; Chowdhury, Tumul; Sandu, Nora; Reck, Martin; Erne, Paul; Schaller, Bernhard; Gharaei., Helen Journal: Medicine Issue: Volume 94:Issue 18(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. (May 2023) Authors: Reck, Martin; Popat, Sanjay; Grohé, Christian; Corral, Jesus; Novello, Silvia; Gottfried, Maya; Brueckl, Wolfgang; Radonjic, Dejan; Kaiser, Rolf; Heymach, John Journal: Lung cancer Issue: Volume 179(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗